Niraparib/abiraterone

Niraparib/abiraterone is a combination of two drugs, Niraparib and Abiraterone, used in the treatment of prostate cancer.

Overview[edit | edit source]

Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor that works by blocking the PARP enzyme, which helps repair damaged DNA in cells. By blocking this enzyme, it can help kill cancer cells. Abiraterone is a type of hormone therapy that works by reducing the amount of testosterone produced by the body, which can slow the growth of prostate cancer cells.

Uses[edit | edit source]

The combination of Niraparib and Abiraterone is used to treat men with metastatic castration-resistant prostate cancer (mCRPC). This is a type of prostate cancer that has spread to other parts of the body and is resistant to medical or surgical treatments that lower testosterone.

Side Effects[edit | edit source]

Common side effects of Niraparib/Abiraterone include fatigue, joint pain, nausea, swelling in the legs or feet, anemia, constipation, vomiting, and diarrhea. More serious side effects can include high blood pressure, heart problems, liver problems, and severe skin reactions.

Precautions[edit | edit source]

Before starting treatment with Niraparib/Abiraterone, patients should inform their healthcare provider about all their medical conditions, including if they have heart problems, liver problems, or a history of skin reactions to medication. They should also inform their healthcare provider about all the medicines they take, as Niraparib/Abiraterone can interact with many other drugs.